Pfizer Inc
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 13, 2026), Pfizer Inc reported 17 stock positions worth $170.4 million. Its top holding was Allogene Therapeutics (ALLO) at 27.5% of the portfolio, followed by Celcuity (CELC, 17.3%) and Arvinas (ARVN, 16.2%). Compared with Q1 2026, it sold out of 1 and reduced 3. The biggest sale was Oric Pharmaceuticals (ORIC, shares −92%).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0000078003
- Portfolio Value
- $170.4M (Q2 2026)
- SEC Filing
- 0000078003-26-000102 ↗ filed Aug 13, 2026
Holdings Value
Holdings 17 stocks · $170.4M
| ALLO Allogene Therapeutics Inc. | 27.55% | 22,032,040 | $46.9M | No change |
| CELC Celcuity Inc. | 17.35% | 295,652 | $29.6M | No change |
| ARVN Arvinas Inc. | 16.24% | 3,457,815 | $27.7M | No change |
| PYXS Pyxis Oncology Inc. | 11.43% | 7,032,770 | $19.5M | No change |
| WVE Wave Life Sciences Ltd. | 6.42% | 1,875,000 | $10.9M | No change |
| BHVN Biohaven Ltd. | 4.70% | 505,645 | $8.0M | No change |
| CRBU Caribou Biosciences Inc. | 4.63% | 4,690,431 | $7.9M | No change |
| SPRO Spero Therapeutics Inc. | 3.13% | 2,362,348 | $5.3M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 2.26% | 953,834 | $3.9M | No change |
| ORIC Oric Pharmaceuticals Inc. | 2.09% | 372,904 | $3.6M | Reduce -92.2% |
| CRDF Cardiff Oncology Inc. | 1.77% | 2,411,575 | $3.0M | No change |
| ZURA Zura Bio Ltd. | 1.69% | 538,841 | $2.9M | Reduce -81.0% |
| AGMB Agomab Therapeutics NV | 0.61% | 75,000 | $1.0M | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.08% | 31,305 | $134K | No change |
| NXTC Nextcure Inc. | 0.04% | 44,347 | $73K | Reduce -71.1% |
| DNA Ginkgo Bioworks Holdings Inc. | 0.02% | 2,928 | $30K | No change |
| SENS Senseonics Holdings Inc. | 0.01% | 2,171 | $12K | No change |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 17 | $170.4M | ALLO, CELC, ARVN, PYXS, WVE |
| Q1 2026 | 18 | $238.8M | ORIC, ALLO, ARVN, CELC, ZURA |
| Q4 2025 | 18 | $236.5M | ORIC, ARVN, CELC, WVE, ALLO |
| Q3 2025 | 21 | $437.5M | BNTX, ORIC, TRML, ARVN, ALLO |
| Q2 2025 | 21 | $576.2M | BNTX, ORIC, ARVN, ALLO, TRML |
| Q1 2025 | 21 | $500.8M | BNTX, ALLO, ORIC, ARVN, TRML |
| Q4 2024 | 23 | $2.6B | HLN, BNTX, ARVN, ALLO, ORIC |